Browsing Tag
NASDAQ VTGN
1 post
Why Vistagen Therapeutics Inc.’s PALISADE-4 trial may matter more than its cash runway
Find out how Vistagen Therapeutics Inc. is advancing PALISADE-4 with $61.8M in cash and tackling placebo risk in CNS trials. Read the analysis.